1. 1) Buford TW. Hypertension and aging. Ageing Res. Rev., 26, 96–111 (2016).
2. 2) Vanhoutte PM, Zhao Y, Xu A, Leung SW. Thirty years of saying NO: sources, fate, actions, and misfortunes of the endothelium-derived vasodilator mediator. Circ. Res., 119, 375–396 (2016).
3. 3) Daiber A, Steven S, Weber A, Shuvaev VV, Muzykantov VR, Laher I, Li H, Lamas S, Munzel T. Targeting vascular (endothelial) dysfunction. Br. J. Pharmacol., 174, 1591–1619 (2017).
4. 4) Matsumoto T, Goulopoulou S, Taguchi K, Tostes RC, Kobayashi T. Constrictor prostanoids and uridine adenosine tetraphosphate: vascular mediators and therapeutic targets in hypertension and diabetes. Br. J. Pharmacol., 172, 3980–4001 (2015).
5. 5) Soh UJ, Dores MR, Chen B, Trejo J. Signal transduction by protease-activated receptors. Br. J. Pharmacol., 160, 191–203 (2010).